Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH EBITDA Margin
EBITDA as a percentage of revenue.
Bio-Techne CorporationNASDAQ: TECH
EBITDA Margin · Q1 FY2027 · quarter ended Sep 2026
EBITDA Margin narrows to 20.2%
EBITDA Margin was 20.2% in Q1 FY2027, down 6.0 pp from a year earlier. On a trailing-twelve-month basis it was 26.8%, up 8.6 pp year over year. Over 3 fiscal years it narrowed by 11.9 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 38.3% for the fiscal year ending Jun 2027, up from 28.3% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 20.2%-8.4 pp QoQ
- Last fiscal yearJun 2026
- 28.3%+10.5 pp YoY
- LTMSep 2026
- 26.8%+8.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -6.0 pp | +10.5 pp | +16.5 pp |
| 1 year | +10.5 pp | +10.0 pp | -0.5 pp |
| 3 years | -11.9 pp | +6.1 pp | +18.0 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 28.3%
- Year-over-year change
- +10.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 28.3% | +10.5pp |
| FY2025 | 2025-06-30 | 17.8% | -9.2pp |
| FY2024 | 2024-06-30 | 27.0% | -13.2pp |
| FY2023 | 2023-06-30 | 40.2% | +2.8pp |
| FY2022 | 2022-06-30 | 37.4% | — |
EBITDA Margin vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 EBITDA Margin of 26.8% is the 4th highest of the 11 companies compared; the peer median is 21.8%.
- Its year-over-year change of +8.6 pp is the 3rd highest of 10, against a peer median of -1.6 pp.
- Over three fiscal years its change of -11.9 pp compares with a peer median of -1.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 33.5% | -1.6 pp | -2.1 pp | |
| LTM Sep 2026 | 27.7% | -0.6 pp | -7.3 pp | |
| LTM Jul 2026 | 27.6% | +1.1 pp | -1.4 pp | |
| LTM Sep 2026 | 26.8% | +8.6 pp | -11.9 pp | |
| LTM Jul 2026 | 26.3% | -3.0 pp | -8.9 pp | |
| LTM Sep 2026 | 23.7% | -2.2 pp | -0.9 pp | |
| LTM Jun 2026 | 19.9% | -6.2 pp | +208.5 pp | |
| LTM Jun 2026 | 7.1% | -4.6 pp | -11.7 pp | |
| LTM Sep 2026 | 6.1% | +10.9 pp | +25.5 pp | |
ALMRAlamar Biosciences, Inc. | FY2025 | -33.5% | — | — |
| LTM Mar 2026 | -427.9% | +95.5 pp | +175.4 pp | |
| Peer median (excluding TECH) | 21.8% | -1.6 pp | -1.4 pp | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B |
| Cost of Revenue | 349.1M | 366.89M | 389.34M | 429.36M | 415.97M |
| Gross Profit | 756.5M | 769.82M | 769.73M | 790.27M | 799.07M |
| Gross Margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Research & Development | 87.14M | 92.49M | 96.66M | 99.5M | 94.77M |
| Selling, General & Admin | 339M | 352.44M | 393.32M | 415.1M | 452.42M |
| Operating Expenses | 459.91M | 470.87M | 563.04M | 688.02M | 547.18M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| EBITDA | 413.76M | 457.11M | 313.14M | 216.88M | 343.44M |
| EBITDA Margin | 37.4% | 40.2% | 27.0% | 17.8% | 28.3% |
| Operating Income | 296.59M | 298.94M | 206.69M | 102.26M | 251.89M |
| Operating Margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Interest Income | 794K | 3.41M | 3.32M | 3.89M | 0 |
| Interest Expense | 11.31M | 11.22M | 15.74M | 8.51M | 5.41M |
| Other Income / Expenses | 4.8M | 39.72M | (21M) | (3.79M) | (11.21M) |
| Income Before Tax | 301.39M | 338.66M | 185.69M | 98.46M | 240.68M |
| Pre-Tax Margin | 27.3% | 29.8% | 16.0% | 8.1% | 19.8% |
| Income Tax Expense | 38.29M | 53.22M | 17.58M | 25.06M | 58.82M |
| Net Income | 272.05M | 285.26M | 168.11M | 73.4M | 181.86M |
| Net Margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (Basic) | 1.73 | 1.81 | 1.07 | 0.47 | 1.17 |
| EPS (Diluted) | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 |
| Weighted Avg Shares | 156.88M | 157.18M | 157.71M | 157.52M | 155.96M |
| Weighted Avg Shares (Diluted) | 164.12M | 161.86M | 160.77M | 159.72M | 157.01M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.